These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15180800)

  • 21. [Shared decision making. The perspective of practicing physicians].
    Floer B; Schnee M; Böcken J; Streich W; Kunstmann W; Isfort J; Butzlaff M
    Med Klin (Munich); 2004 Aug; 99(8):435-40. PubMed ID: 15309271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
    Créange A; Debouverie M; Jaillon-Rivière V; Taithe F; Liban D; Moutereau A; Clavelou P; Defer G
    Mult Scler; 2009 Sep; 15(9):1085-91. PubMed ID: 19556312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preferences for shared decision making in chronic pain patients compared with patients during a premedication visit.
    Spies CD; Schulz CM; Weiss-Gerlach E; Neuner B; Neumann T; von Dossow V; Schenk M; Wernecke KD; Elwyn G
    Acta Anaesthesiol Scand; 2006 Sep; 50(8):1019-26. PubMed ID: 16923100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapse management in multiple sclerosis.
    Thrower BW
    Neurologist; 2009 Jan; 15(1):1-5. PubMed ID: 19131851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A shared decision-making communication training program for physicians treating fibromyalgia patients: effects of a randomized controlled trial.
    Bieber C; Müller KG; Blumenstiel K; Hochlehnert A; Wilke S; Hartmann M; Eich W
    J Psychosom Res; 2008 Jan; 64(1):13-20. PubMed ID: 18157994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of a shared decision-making intervention on physician-patient interaction and outcome in fibromyalgia. A qualitative and quantitative 1 year follow-up of a randomized controlled trial.
    Bieber C; Müller KG; Blumenstiel K; Schneider A; Richter A; Wilke S; Hartmann M; Eich W
    Patient Educ Couns; 2006 Nov; 63(3):357-66. PubMed ID: 16872795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FTY720 (fingolimod) for relapsing multiple sclerosis.
    Horga A; Montalban X
    Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The natural history of relapses in multiple sclerosis.
    Vollmer T
    J Neurol Sci; 2007 May; 256 Suppl 1():S5-13. PubMed ID: 17346747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Shared decision-making based on equal information. Patient guidelines as a tool for patient counseling].
    Sänger S; Kopp I; Englert G; Brunsmann F; Quadder B; Ollenschläger G
    Med Klin (Munich); 2007 Jun; 102(6):474-9. PubMed ID: 17571222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-centered informed consent in surgical practice.
    Bernat JL; Peterson LM
    Arch Surg; 2006 Jan; 141(1):86-92. PubMed ID: 16415417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A generic tool for development of decision aids based on clinical practice guidelines.
    Raats CJ; van Veenendaal H; Versluijs MM; Burgers JS
    Patient Educ Couns; 2008 Dec; 73(3):413-7. PubMed ID: 18768285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
    Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.